- Reports: ESI may start 'price war' over new hepatitis C drugs
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- FDA's Janet Woodcock not to retire
DEERFIELD, Ill. — The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.
Takeda announced that the FDA issued a complete response letter for its regulatory applications for the Type 2 diabetes drug alogliptin and a combination pill that includes alogliptin and pioglitazone, the active ingredient in the drug Actos.
A complete response letter means that the FDA has finished reviewing a drug approval application, but questions remain that preclude approval. In this case, the agency requested additional data about the drugs, which Takeda said it would supply from clinical trials.